On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...